Subject
Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Medicine
Reference16 articles.
1. European AIDS Clinical Society. EACS guidelines. Version 11.0. Brussels: European AIDS Clinical Society; 2021. Available at: https://www.eacsociety.org/media/final2021eacsguidelinesv11.0_oct2021.pdf [accessed 5 June 2022].
2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Available at: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf [accessed 5 June 2022].
3. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study;Molina;Lancet HIV,2015
4. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection;Walmsley;N Engl J Med,2013
5. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials;Orkin;Lancet HIV,2020